Aripiprazole Tablet
Product Images NDC 62332-102

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 62332-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure diagram depicting the molecular structure of aripiprazole, showing rings and functional groups consistent with the active ingredient in the product Aripiprazole tablets by Alembic Pharmaceuticals Inc.*

FDA Label Image

Aripiprazole-figure1.jpg (Aripiprazole Figure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' displaying fold changes with 90% confidence intervals for AUC and Cmax pharmacokinetic parameters. It compares the impact of various interacting drugs such as CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam) on aripiprazole exposure relative to a reference without interacting drug.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence interval in AUC and Cmax of dehydro-aripiprazole with various interacting drugs, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam. The x-axis represents change relative to reference without interacting drug.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

A horizontal bar chart showing fold change with 90% confidence intervals for pharmacokinetic (PK) parameters (AUC and Cmax) of various drugs interacting with enzymes CYP2D6, CYP2C9, CYP2C19, and UGT1A4. The x-axis is labeled 'Change Relative to Reference (without interacting drug)' ranging approximately from 0 to 3. Individual drugs include dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, and venlafaxine (along with O-desmethylvenlafaxine). The y-axis displays drug names alongside the measured PK parameters.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

Pharmacokinetic chart showing Aripiprazole fold change and 90% confidence intervals for various special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with axes representing change relative to reference for AUC and Cmax values.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic fold change chart showing Dehydro-Aripiprazole exposure relative to reference in different populations. Factors compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference (0.5 to 3), with fold change and 90% confidence intervals plotted for AUC and Cmax values.*

FDA Label Image

Aripiprazole-fig-6.jpg (Aripiprazole Fig 6)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over 182 days from randomization. The graph compares two groups: Aripiprazole (solid line) and Placebo (dashed line). The X-axis represents days from randomization, and the Y-axis represents the proportion with relapse. The number of subjects at risk is displayed below the X-axis at various time points for both groups.*

FDA Label Image

Figure 7 (Aripiprazole Figur7)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The chart includes the number of subjects at risk at different time points for both groups, illustrating relapse trends over approximately 182 days.*

FDA Label Image

Aripiprazole-fig-9.jpg (Aripiprazole Fig 9)

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares Aripiprazole at low and high doses to placebo, with least-squares mean changes plotted on the vertical axis and weeks of treatment on the horizontal axis. Both Aripiprazole doses demonstrate a greater reduction in tic scores compared to placebo over time.*

FDA Label Image

30 Tablets (Aripiprazole 2mg)

Aripiprazole Tablets, USP 2 mg oral tablet label by Alembic Pharmaceuticals Inc. The label includes dosing instructions to store at 20°C with permitted excursions, a note that the package is child-resistant, and warnings to dispense with medication guide. The package contains 30 tablets and features a barcode and NDC 62332-097-30.*

FDA Label Image

30 Tablets (Aripiprazole 5mg)

Aripiprazole Tablets, USP 5 mg oral tablets label by Alembic Pharmaceuticals Inc. The label states each tablet contains 5 mg aripiprazole and includes storage instructions. The package contains 30 tablets and is marked Rx only with directions for pharmacist dispensing. Manufacturer information for Alembic Pharmaceuticals, Inc. is also displayed along with the NDC 62332-098-30 and barcode.*

FDA Label Image

30 Tablets (Aripiprazole 10mg)

Label for Aripiprazole Tablets, USP 10 mg oral tablets, with a package quantity of 30 tablets. The label includes storage instructions, manufacturer Alembic Pharmaceuticals Inc., and labeling details such as NDC 62332-099-30 and a barcode. It states 'Pharmacist: Dispense with medication guide' and includes the Alembic logo.*

FDA Label Image

30 Tablets (Aripiprazole 15mg)

Label for Aripiprazole Tablets, USP 15 mg oral tablets by Alembic Pharmaceuticals Inc. The label includes dosage strength, NDC 62332-100-30, package quantity of 30 tablets, and storage instructions. It features the Alembic logo and states Rx only with dispensing instructions.*

FDA Label Image

30 Tablets (Aripiprazole 20mg)

Aripiprazole Tablets, USP 20 mg oral tablets packaging label from Alembic Pharmaceuticals Inc. The label indicates 30 tablets per container with NDC 62332-101-30. Storage instructions and manufacturer details for Alembic Pharmaceuticals Limited in India and Alembic Pharmaceuticals, Inc. in the USA are included. The label includes a note to dispense with medication guide.*

FDA Label Image

30 Tablets (Aripiprazole 30mg)

Aripiprazole Tablets, USP 30 mg blister pack label from Alembic Pharmaceuticals Inc. The label includes dosage strength (30 mg), NDC number 62332-102-30, quantity of 30 tablets, and mentions dispensing with medication guide. Storage instructions and manufacturer details for Alembic Pharmaceuticals Limited (India) and Alembic Pharmaceuticals, Inc. (USA) are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.